Oscar Health (ticker: OSCR) experienced a volatile trading session, initially dropping 5% before rallying 10%. Despite this short-term price strength and technical indicators suggesting a potential bullish setup, analysts remain cautious. Barclays maintained an 'Underweight' rating on the stock and lowered its price target from $17.00 to $11.00, reflecting a 35.29% reduction. Jefferies also kept an 'Underperform' rating and cut its price target from $9.00 to $8.00, citing aggressive guidance and a $500 million cut in EBIT, with expectations of further margin declines. The stock's rally amid negative news puzzled some analysts, who noted the absence of a capital raise and that the increase in the 2025 medical loss ratio (MLR) by 530 basis points was less severe compared to competitors Centene Corp (CNC) and Elevance Health (ELV). Meanwhile, Enphase Energy (ENPH) saw its price target trimmed by Oppenheimer from $86.00 to $77.00 due to slower European demand and a transition in U.S. lease contracts, although the firm maintained an 'Outperform' rating based on margin recovery potential.